nach oben

Journal für Gastroenterologische und Hepatologische Erkrankungen

15.05.2024 | Originalien

Diabetes mellitus bei Patient:innen mit Leberzirrhose – eine besondere therapeutische Herausforderung

verfasst von: PD Dr. Claudia Ress, PhD

Erschienen in: Journal für Gastroenterologische und Hepatologische Erkrankungen

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Therapie des Diabetes mellitus bei Patient:innen mit gleichzeitig bestehender Leberzirrhose stellt eine besondere therapeutische Herausforderung dar. Die Leber ist ein zentrales Organ der Glukosehomöostase und daher sind Erkrankungen, welche mit einer Einschränkung der Leberfunktion einhergehen auch häufig mit Störungen im Glukosemetabolismus vergesellschaftet. Eine Leberzirrhose kann hierbei, je nach aktuellem Krankheitsstadium mit einer ausgeprägten Insulinresistenz oder einem stark erhöhten Hypoglykämierisiko einhergehen. Die Ursachen für diese stark wechselnden Effekte auf den Glukosestoffwechsel sind multifaktoriell und werden durch hepatische und systemische Faktoren verursacht. Die stark eingeschränkten therapeutischen Möglichkeiten zur Behandlung des Diabetes mellitus bei fortgeschrittener Leberzirrhose und die dadurch häufige Notwendigkeit der Insulintherapie spielen hier ebenfalls eine Rolle. Andererseits kann sich eine schlechte glykämische Kontrolle negativ auf den Verlauf von hepatischen Erkrankungen auswirken, sodass eine gute glykämische Kontrolle insbesondere in diesem Kollektiv von großer Bedeutung ist.

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 71(4):793–801CrossRefPubMed

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM (2015) Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62(5):1148–1155CrossRefPubMed

de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M (1999) Cause-specific mortality in type 2 diabetes. The verona diabetes study. Diabetes Care 22(5):756–761CrossRefPubMed

Arvanitakis K, Koufakis T, Kalopitas G, Papadakos SP, Kotsa K, Germanidis G (2023) Management of type 2 diabetes in patients with compensated liver cirrhosis: short of evidence, plenty of potential. Diabetes Metab Syndr 28;18(1):102935CrossRef

García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE et al (2012) The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol 11(2):240–248CrossRefPubMed

Asrih M, Jornayvaz FR (2015) Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Mol Cell Endocrinol 418:55–65CrossRefPubMed

Fromenty B, Roden M (2023) Mitochondrial alterations in fatty liver diseases. J Hepatol 78(2):415–429CrossRefPubMed

Champion C, Neagoe RM, Effernberger M, Sala DT, Servant F, Christensen JE et al (2023) Human liver microbiota modeling strategy at the early onset of fibrosis. BMC Microbiol 30;23(1):34CrossRef

Puri P, Kotwal N (2022) An approach to the management of diabetes mellitus in cirrhosis: A primer for the hepatologist. J Clin Exp Hepatol 12(2):560–574CrossRefPubMed

10.

de Vries M, Westerink J, Kaasjager KHAH, de Valk HW (2020) Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 1;105(12):3842–3853CrossRefPubMed

11.

Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S et al (2023) A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 78(3):471–478CrossRefPubMed

12.

Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14(1):32–42CrossRefPubMed

13.

Zachou K, Azariadis K, Lytvyak E, Snijders RJALM, Takahashi A, Gatselis NK et al (2023) Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease. Jhep Rep Innov Hepatol 5(8):100778CrossRef

14.

Wang X, Wei S, Wei Y, Wang X, Xiao F, Feng Y et al (2023) The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study. Eur J Gastroenterol Hepatol 35(8):889–898CrossRefPubMed

15.

Clodi M, Abrahamian H, Brath H, Schernthaner G, Brix J, Ludvik B et al (2023) Antihyperglycemic treatment guidelines for diabetes mellitus type 2 (Update 2023). Wien Klin Wochenschr 135(Suppl 1):32–44CrossRefPubMedPubMedCentral

16.

Tsamos G, Vasdeki D, Koufakis T, Michou V, Makedou K, Tzimagiorgis G (2023) Therapeutic potentials of reducing liver fat in non-alcoholic fatty liver disease: close association with type 2 diabetes. Metabolites 4;13(4):517CrossRefPubMed

17.

Dixon JB, Bhathal PS, O’Brien PE (2006) Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. OBES SURG 16(10):1278–1286CrossRefPubMed

18.

Caiazzo R, Lassailly G, Leteurtre E, Baud G, Verkindt H, Raverdy V et al (2014) Roux-en‑Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 260(5):893–898CrossRefPubMed

19.

Zm Y, Ke C, Jk L (2021) AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology 160(3)

20.

Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T et al (2019) ESPEN guideline on clinical nutrition in liver disease. Clin Nutr Edinb Scotl 38(2):485–521CrossRef

21.

Calmet F, Martin P, Pearlman M (2019) Nutrition in patients with cirrhosis. Gastroenterol Hepatol 15(5):248–254

22.

Akiyama H, Nishimura A, Morita N, Yajima T (2023) Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Front Endocrinol 14:1111984CrossRef

23.

B L, Y W, Z Y, H Y, X C, Z W et al (2018) Effects of canagliflozin on fatty liver indexes in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm [internet] 21(1)

24.

Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K et al (2022) Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 6(11):3073–3082CrossRefPubMedPubMedCentral

25.

Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Babaei RM et al (2020) Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial. Adv Ther 37(11):4697–4708CrossRefPubMedPubMedCentral

26.

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet Lond Engl 387(10019):679–690CrossRef

27.

Lee HA, Kim HY (2023) Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci 26;24(11):9324CrossRef

28.

Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165(5):305–315CrossRefPubMed

29.

Ndakotsu A, Vivekanandan G (2022) The role of thiazolidinediones in the amelioration of nonalcoholic fatty liver disease: a systematic review. Cureus 14(5)

30.

Zhang A, Qian F, Li Y, Li B, Yang F, Hu C et al (2023) Research progress of metformin in the treatment of liver fibrosis. Int Immunopharmacol 116:109738CrossRefPubMed

31.

Yang T, Guan Q, Shi JS, Xu ZH, Geng Y (2023) Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF‑1 in the gut microbiota. Biochim Biophys Acta Mol Basis Dis 1869(5):166664CrossRefPubMed

32.

Su Y, Hou C, Wang M, Ren K, Zhou D, Liu X et al (2023) Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis. Int J Biochem Cell Biol 157:106375CrossRefPubMed

33.

Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 1;19(5):537–544CrossRef

34.

Yen FS, Huang YH, Hou MC, Hwu CM, Lo YR, Shin SJ et al (2022) Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis. Br J Clin Pharmacol 88(1):311–322CrossRefPubMed

35.

Maaly AE, Haidy K, Shahinaz S (2021) Hepatoprotective effect of linagliptin against liver fibrosis induced by carbon tetrachloride in mice. Can J Physiol Pharmacol 99(3):294–302. https://doi.org/10.1139/cjpp-2020-0049CrossRef

36.

Kim NH, Yu T, Lee DH (2014) The nonglycemic actions of dipeptidyl peptidase-4 inhibitors. Biomed Res Int 2014:368703CrossRefPubMedPubMedCentral

37.

Petroni ML, Brodosi L, Marchesini G (2023) The treatment of diabetes in advanced liver disease: change of a paradigm. Ann Hepatol 28(1):100772CrossRefPubMed

38.

Yen FS, Hou MC, Liu JS, Hsu CC, Hwu CM (2022) Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes. Front Med 9:962337CrossRef

39.

Inagaki N, Sheu WHH, Owens DR, Crowe S, Bhandari A, Gong Y et al (2016) Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. J Diabetes Complications 30(8):1622–1630CrossRefPubMed

40.

Yen FS, Wei JCC, Yip HT, Hwu CM, Hou MC, Hsu CC (2021) Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan. Hepatol Int 15(1):179–190CrossRefPubMed

41.

Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K et al (2010) Linagliptin (BI 1356), a potent and selective DPP‑4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med J Br Diabet Assoc 27(12):1409–1419CrossRef

42.

Mariam Z, Niazi SK (2024) Glucagon-like peptide agonists: A prospective review. Endocrinol Diabetes Metab 7(1):e462CrossRefPubMed

Titel: Diabetes mellitus bei Patient:innen mit Leberzirrhose – eine besondere therapeutische Herausforderung
verfasst von: PD Dr. Claudia Ress, PhD
Publikationsdatum: 15.05.2024
Verlag: Springer Vienna
Erschienen in: Journal für Gastroenterologische und Hepatologische Erkrankungen
Print ISSN: 1728-6263
Elektronische ISSN: 1728-6271
DOI: https://doi.org/10.1007/s41971-024-00191-6

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten